NPPB and cancer: The recent guidelines on cardio-oncology developed in collaboration with the European Hematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society [21] have emphasized the significance of cardiac-specific biomarkers, including B-type natriuretic peptide (BNP) and cardiac troponin (cTn), in enhancing the traditional echocardiographic assessment of cardiotoxicity linked to cancer treatments.